Compare ResMed Inc. (RMD) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Growth Index Fund ETF — how do they compare? ResMed Inc. trades at $196 (market cap $28.81B), while Vanguard Growth Index Fund ETF trades at $86.16. The key difference: ResMed Inc. pays a 1.21% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | VUG | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | Sector/Thematic |
52-Week High | $293.73 | $90.29 |
52-Week Low | $182.82 | $70.00 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VUG trades at $85.32, up 0.06% with a bearish technical signal from moving averages. The ETF's low expense ratio of 0.03% and strong historical returns, including a 411% total return over the past decade per The Motley Fool (2026-07-12), highlight its cost efficiency. Recent news emphasizes its growth focus and tech-heavy holdings, with a stock split executed on 21 April 2026. Support levels are clustered around $84-$85, indicating potential near-term stability.
Outlook remains positive for long-term investors due to VUG's low-cost structure and exposure to high-growth U.S. large-cap stocks. Risks include high concentration in technology sectors and market volatility. Analyst sentiment is generally favorable, supporting a buy-and-hold strategy for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
